Genelux Corporation

Stage 4 · Declining · week 11

As of Oct 22, 2026, Genelux is in Stage 4, the downtrend phase, now in week 11 (since Aug 10, 2026). It closed at $1.98, 76.0% below its 52-week high and below its 200-day average, which is falling.

$1.98

-4.35% today

$89.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is GNLX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 44w

S1 16w

S2 20w

S1 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 12w → S4 44w → S1 16w → S4 4w → S2 10w → S3 5w → S4 6w → S1 5w → S2 20w → S3 6w → S4 13w → S1 13w → S4 11w current

Total tracked: 165 weeks across 13 stage runs.

GNLX among Biotechnology427th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…427	GNLXGenelux Corporation	Stage 4 · wk 11	15	−21.3%

vs 52W High

-76.0%

$1.98 lo$8.24 hi

76.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 11

1w13w26w

Week 11, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-27.1%

200 DMA: $2.72 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

3.14x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-21.3%

-31.5%

-21.4%

YTD

-56.5%

-70.5%

Scan Membership

Breakout Watch

Latest: 2025-01-30

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 11 · Vol 3.14x

2026-10-21S4

Wk 11 · Vol 2.92x

2026-10-20S4

Wk 11 · Vol 1.13x

2026-10-19S4

Wk 10 · Vol 0.55x

2026-10-16S4

Wk 10 · Vol 0.95x

2026-10-15S4

Wk 10 · Vol 2.69x

2026-10-14S4

Wk 10 · Vol 1.35x

2026-10-13S4

Wk 10 · Vol 0.50x

2026-10-12S4

Wk 9 · Vol 0.23x

2026-10-09S4

Wk 9 · Vol 0.49x

2026-10-08S4

Wk 9 · Vol 0.83x

2026-10-07S4

Wk 9 · Vol 1.82x

Moving averages & range

50 DMA

$2.54

200 DMA

$2.72

52W High

$8.24

52W Low

$1.98

5D Low

$1.98

Resistance levels (recent highs)

20d High

$2.60

60d High

$3.05

120d High

$3.19

250d High

$8.24

Next resistance

+31.3%

to 20d High

ROE

-177.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 5.5

Genelux: quick answers

What stage is Genelux in?

As of Oct 22, 2026, Genelux (GNLX) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 10, 2026 and is in week 11. What the four stages mean

Is Genelux in an uptrend?

No. Genelux is in a Stage 4 downtrend. It trades 27.1% below its 200-day average, which is falling.

How far is Genelux from its 52-week high?

Genelux closed at $1.98 on Oct 22, 2026, 76.0% below its 52-week high of $8.24. Its 52-week low is $1.98.

How has Genelux performed over the past year?

As of Oct 22, 2026, Genelux is down 70.5% over the past year and down 56.5% so far in 2026.

Which sector and industry is Genelux in?

Genelux is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.